(Press Release) ALLVP announced its investment in Medica Santa Carmen SAPI de CV through its second investment vehicle Venture Innovation Fund II. The US$7m (more than MXN$100m pesos) investment round will allow the company to grow from 3 to 25 clinics in 2019.

Medica Santa Carmen, a state-of-the-art network of low cost integral care centers for patients with kidney failure, has a unique value proposition that offers hemodialysis treatments complemented by integral consultations delivered by nephrologists, nutritionists and psychologists. Operating its first clinic since December 2011, Santa Carmen has performed over 40,000 treatments with a zero mortality rate during sessions. “The capital injected will help the company scale its footprint to reach more patients who lack access to quality and cost effective treatment, leveraging its business model based on patient safety, experience and best clinical results. Our mission is to provide life-wellbeing to people with end stage renal disease and to go beyond in helping reverse the incidence of irreversible kidney disease,” said Andres Gutierrez, founder and CEO of Medica Santa Carmen.

Santa Carmen has developed blueprint processes to scale as the leader in cost and quality, as it prepares for its high-growth stage executing on its vision to become the highest impact clinic network in Mexico. The company has been recognized as an innovator by the International Partnership in Innovative Healthcare Delivery Network (www.ipihd.org) and its three clinics hold ISO9001 and General Health Ministry Certifications. “We had been carefully looking for a star-company to deploy our first investment and launch the operations of our recently created fund. Due to its high quality, innovative health-care services, accelerated growth and remarkable execution, the company became the perfect target” said Juan Sandoval, Managing Director of Fondo de Impacto Social of Nacional Monte de Piedad.

Mexico leads the world in obesity, diabetes and now Chronic Kidney Disease (CKD), as a consequence. According to the National Kidney Foundation, 1:1,000 people are at risk, whereas in Mexico, 1:800 are at risk. There are 150,000 diagnosed patients with chronic renal failure, a number that is expected to grow 10-15% annually. In that situation, patients waiting for a renal transplant can access a shorter and safer treatment through hemodialysis, proven to be the most cost-effective. The current market segment for hemodialysis is 20,000 patients, representing an estimated value of USD$500 million per year. “We believe that the sector is highly attractive due to the market’s expected growth, the insufficient and low-quality supply and the scalable and replicable model of this innovative solution” said Fernando Lelo de Larrea, Managing Partner of ALLVP and investor in Medica Santa Carmen.